Overview

A Study in Recurrent Glioblastoma (GB)

Status:
Active, not recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Lomustine